[PDF][PDF] A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells

S Cheng, Z Li, R Gao, B Xing, Y Gao, Y Yang, S Qin… - Cell, 2021 - cell.com
Tumor-infiltrating myeloid cells (TIMs) are key regulators in tumor progression, but the
similarity and distinction of their fundamental properties across different tumors remain elusive. …

Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study

W Gao, J Weng, Y Gao, X Chen - BMC infectious diseases, 2013 - Springer
Background The female genital tract is an important bacterial habitat of the human body,
and vaginal microbiota plays a crucial role in vaginal health. The alteration of vaginal …

The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia

C Zhang, Y Liu, W Gao, Y Pan, Y Gao, J Shen… - Cancer …, 2018 - Wiley Online Library
Cervical microbiota composition is associated with cervical HPV infection and CIN severity.
Previous studies only assessed the total association between cervical microbiota and HPV …

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre …

X Gao, N Xu, Z Li, L Shen, K Ji, Z Zheng, D Liu… - The Lancet …, 2023 - thelancet.com
Background Immune checkpoint inhibitors targeting PD-1 or CTLA-4 individually have
shown substantial clinical benefits in the treatment of malignancies. We aimed to assess the …

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

L Xia, Q Zhou, Y Gao, W Hu, G Lou, H Sun… - Nature …, 2022 - nature.com
This phase 2 study assesses the efficacy and safety of camrelizumab (an anti-PD-1 antibody)
plus famitinib (anti-angiogenic agent) in women with pretreated recurrent or metastatic …

Evaluation of the sexual quality of life and sexual function of cervical cancer survivors after cancer treatment: a retrospective trial

X Wu, L Wu, J Han, Y Wu, T Cao, Y Gao… - Archives of Gynecology …, 2021 - Springer
Objective The purpose of this study was to explore the factors influencing the sexual quality
of life of patients with cervical cancer who underwent radical hysterectomy. Methods This …

[HTML][HTML] Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter …

…, Q Zhou, W Hu, H Shi, L Wang, Y Gao… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Combination treatments with immune-checkpoint inhibitor and antiangiogenic
therapy have the potential for synergistic activity through modulation of the microenvironment …

Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort

L Wu, J Zhu, R Yin, X Wu, G Lou, J Wang, Y Gao… - Gynecologic …, 2021 - Elsevier
Purpose Maintenance therapy with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib
provided a substantial progression-free survival (PFS) benefit compared with placebo in …

Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease

H Zheng, Y Gao - International Journal of Gynecologic Cancer, 2012 - ijgc.bmj.com
Objective To evaluate the role of the novel tumor marker human epididymal secretory protein
E4 (HE4) in discriminating ovarian cancer from benign pelvic disease in patients with a …

Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter …

…, W Sun, Q Zhou, S Zhang, D Wang, H Shi, Y Gao… - Clinical Cancer …, 2022 - AACR
Purpose: Phase I results of this phase I/II study showed that pamiparib 60 mg twice a day
had antitumor activity and an acceptable safety profile in Chinese patients with advanced …